Zura Bio falls after commencing stock offering

Zura Bio

24/02/2026 22:00

** Zura Bio's ZURA.O shares down 4.8% in extended trading to $6.37 after planned equity raise news

** Autoimmune and inflammatory diseases firm announces offering of shares and pre-funded warrants; deal size not disclosed

** It intends to use net offering proceeds for working capital, advance its pipeline, and general purposes, per the prospectus

** Co says its lead product candidate, tibulizumab, being evaluated in mid-stage studies for autoimmune conditions hidradenitis suppurativa and systemic sclerosis

** Leerink Partners, Piper Sandler and Cantor Fitzgerald joint bookrunners for offering

** Henderson, Nevada-headquartered co has ~73.7 mln shares outstanding, per LSEG data, for nearly $500 mln market cap

** ZURA shares on Tues closed up 2.5% at $6.69. Stock up ~28% YTD after more than doubling in 2025

** All 8 analysts are bullish including 4 "strong buy" ratings; median PT $15, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))